Skip to main content

How Powerful Is COVID-19?

  • Author:
  • Updated date:


Several unexplained pneumonia cases of etiology were notified to the World Health Organization (WHO) by the Chinese Health Authority in Wuhan Area, Hubei Province, Central China, on 31 December 2019 [1]. Cases have been recorded since 8 December 2019 [2]. Many patients were either employed or residing in the local wholesale market for Huanan Seafood, while other early issues were not exposed [3]. On 7 January, a novel coronavirus was reported in a patient swab study [4]. The disease was subsequently transformed into Coronavirus 2 Severe Acute Respiratory Syndrome (SARS-CoV-2) and was referred to as Coronavirus Disease 2019 (COVID-19) by the WHO [5].

The Powerful Outbreak

As of 30 January, China has had 7,736 suspicious cases and 12,167 suspected cases, and in 18 other counties, 82 verified cases have been found [6]. It was announced that the SARS-CoV-2 outbreak was an International Public Health Emergency (PHEIC) on the same day. By 4 February, the registered death rate in China was 2.1%, while for non-China, the Chinese National Health Commission claimed the death rate was 0.2% [7]. The mortality rates for admitted patients in hospitals ranged from 11% to 15%. COVID-19 is moderately infectious, but the accessible information is gradually growing in public documents and newspapers [8].

SARS-CoV-2 belongs to the families of Coronaviridae and Nidovirales. SARS-CoV-2 is an RNA (+ ssRNA) virus single-stranded, enveloped, and positively sensed [9]. SARS-CoV-2 is a novel infection of Betacoro-navirus [10]. The study of the SARS-CoV-2 genome indicates that the virus has a strong relationship with two bat-driven coronaviruses (bat-SL-CoVZC 45 and bat-SL-CoVZXC21) in eastern China from the 2018 SARS-CoV and MERS-CoV [11].

Further study has shown that the virus is more linked to BatCoV RaTG13, which was previously used in the Rhine affinism in Yunnan Province, as well as the usage of SARS-CoV-2, RaTG13, and SARS-CoV gene sequences [12]. 96,2% of the total genome recognition [13]. No proof was identified for recombinant events in the SARS-CoV-2 genome in other bat viruses, such as BatCoV RaTG13, SARS-CoV, and SARSR-CoV [14]. Both these findings suggest that the original host of this virus is maybe bats [15].

An examination, however, is essential to decide whether intermediate hosts have authorized human virus transmission [16]. Bats are not specifically accountable organisms for the infection spread to humans for different purposes [17]. Certain non-water goods like mammals were introduced into the wholesale sector of Huanan Seafood, but talks were sold or detected [18]. The Nipah virus in Bangladesh, for example, is transmitted through bats to raw palm sap [19].

The Huanan Seafood Wholesale Market's role in the dissemination of diseases is unknown [20]. Many of COVID-19's first findings suggest that SARS-CoV-2 has spread from animals to people [21]. However, the genomic study showed that the virus is imported from an unrevealed region to the industry where it spreads further [22]. It should have become more acute for humans and people at the same moment [23]. The existence of an individual infection has been confirmed by associations of families and medical personnel involved [4].

Less than 10% of patients had visibility on the market, and more than 70% had no exposure to the market after 1 January [24]. Person-to-person transmission between contacts is predicted to occur mainly through respiratory gout while the person is afflicted with tabs or sneezes [25]. SARS CoV lived up to 96 hours on surfaces and certain coronaviruses for up to 9 days [26]. Fomites may be a useful transmitting source if asymptomatic disorders are troublesome or not [27]. The initial report published on 30 January reported asymptomatic transmission, but the patient with symptoms received no clear interviews before the condition was conveyed [28].

In recent research published on 21 February, the asymptomatic transmission was alleged, but mistakes in self-reported symptoms or other cases and fomites can limit these results [29]. The effects of disease features shift rapidly and are subject to selection variations [30]. The mean incubation period in the study was 5.2 days. It was found that the incubation period was 19 or 24 days [31].

In the new situation, all sectors of society have been affected by COVID-19 [32]. There is a massive deficit in the world because it cannot be assessed precisely [33]. Today's world is like a cold war in which everyone wants to control everything. Many countries often contain a wide range of products, such as medicines, vehicles, motor vehicles, computers, and mobile phones [34]. The products are typically produced in separate nations. It acts like a chain mechanism that blocks progress since even one chain link collapses. China is the largest producer of different components, and China is also the country with the most significant impact on COVID-19 [35]. The global economy is seriously affected by the collapse of global production [36]. Any nation has been prohibited from traveling, ensuring that airlines and travel companies earn millions of dollars less [37]. Drugs, sanitizers, gloves, and other products are limited, and the cost of these things is increased [38].

Various functions are proposed to avoid significant social impacts, such as scientific conferences, business programs, sports competitions, fashion events, and marriages [39]. For Mecca and Medina tourists, Umrah has been banned by the Kingdom of Saudi Arabia [40]. All of these developments have had a significant impact on the domestic and global capital markets [41]. Since 2008, the S&P 500 Benchmark, NASDAQ-100, Dow Jones Industrial Average have been major stock benchmarks [42]. Classrooms, schools, and universities have been banned in many countries, and millions of students have not been taught at an excellent standard stage. This loss is tough to measure in terms of income, but it is a significant disadvantage for students and their families [43]. In short, the global economy is suffering massive declines, with the economist forecasting a deficit of some US$ 2.7 trillion [44].


Unani treatment and allopathic medicine may be useful. The number of cases of COVID-19 may be lower in the coming summer, and the rate of transmission of the virus may decrease at high temperatures and humidity. This disease extends to people who do not take it seriously and do not agree with the WHO and the local government's orders. Therefore, all residents must be intensely monitored by mitigation, administration, and quarantine without religious differences. If not, that might be the worst scenario. Our young generation needs to be educated in science and technology to deal with such disasters in the future. There is no cause for concern, and it is necessary to prevent and treat this disease effectively. Briefly, coordinated efforts are expected globally to combat such conditions in the future without religious differences.


[1] E. B. Kpozehouen, X. Chen, M. Zhu, and C. R. Macintyre, “Using Open-Source Intelligence to Detect Early Signals of COVID-19 in China: Descriptive Study,” JMIR Public Heal. Surveill., vol. 6, no. 3, p. e18939, Sep. 2020, doi: 10.2196/18939.

[2] G. La Rosa et al., “SARS-CoV-2 has been circulating in northern Italy since December 2019: Evidence from environmental monitoring,” Sci. Total Environ., vol. 750, p. 141711, Jan. 2021, doi: 10.1016/j.scitotenv.2020.141711.

[3] F. A. Rabi, M. S. Al Zoubi, G. A. Kasasbeh, D. M. Salameh, and A. D. Al-Nasser, “SARS-CoV-2 and Coronavirus Disease 2019: What We Know So Far,” Pathogens, vol. 9, no. 3, p. 231, Mar. 2020, doi: 10.3390/pathogens9030231.

[4] J. F. W. Chan et al., “A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster,” Lancet, vol. 395, no. 10223, pp. 514–523, Feb. 2020, doi: 10.1016/S0140-6736(20)30154-9.

[5] A. E. Gorbalenya et al., “The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2,” Nat. Microbiol., vol. 5, no. 4, pp. 536–544, Apr. 2020, doi: 10.1038/s41564-020-0695-z.

[6] Z. Allam, “The Second 50 days: A Detailed Chronological Timeline and Extensive Review of Literature Documenting the COVID-19 Pandemic From Day 50 to Day 100,” in Surveying the Covid-19 Pandemic and its Implications, Elsevier, 2020, pp. 9–39.

[7] R. Tariq, S. Saha, F. Furqan, L. Hassett, D. Pardi, and S. Khanna, “Prevalence and Mortality of COVID-19 Patients With Gastrointestinal Symptoms: A Systematic Review and Meta-analysis,” Mayo Clin. Proc., vol. 95, no. 8, pp. 1632–1648, Aug. 2020, doi: 10.1016/j.mayocp.2020.06.003.

[8] G. Giordano et al., “Modelling the COVID-19 epidemic and implementation of population-wide interventions in Italy,” Nat. Med., vol. 26, no. 6, pp. 855–860, Jun. 2020, doi: 10.1038/s41591-020-0883-7.

Scroll to Continue

[9] M. Pal, G. Berhanu, C. Desalegn, and V. Kandi, “Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2): An Update,” Cureus, vol. 12, no. 3, p. e7423, Mar. 2020, doi: 10.7759/cureus.7423.

[10] S. Dong, J. Sun, Z. Mao, L. Wang, Y. Lu, and J. Li, “A guideline for homology modeling of the proteins from newly discovered betacoronavirus, 2019 novel coronavirus (2019‐nCoV),” J. Med. Virol., vol. 92, no. 9, pp. 1542–1548, Sep. 2020, doi: 10.1002/jmv.25768.

[11] M. Sironi et al., “SARS-CoV-2 and COVID-19: A genetic, epidemiological, and evolutionary perspective,” Infect. Genet. Evol., vol. 84, p. 104384, Oct. 2020, doi: 10.1016/j.meegid.2020.104384.

[12] Y. Yan et al., “The First 75 Days of Novel Coronavirus (SARS-CoV-2) Outbreak: Recent Advances, Prevention, and Treatment,” Int. J. Environ. Res. Public Health, vol. 17, no. 7, p. 2323, Mar. 2020, doi: 10.3390/ijerph17072323.

[13] T. Zhang, Q. Wu, and Z. Zhang, “Probable Pangolin Origin of SARS-CoV-2 Associated with the COVID-19 Outbreak,” Curr. Biol., vol. 30, no. 8, p. 1578, Apr. 2020, doi: 10.1016/j.cub.2020.03.063.

[14] P. Zhou et al., “A pneumonia outbreak associated with a new coronavirus of probable bat origin,” Nature, vol. 579, no. 7798, pp. 270–273, Mar. 2020, doi: 10.1038/s41586-020-2012-7.

[15] L.-F. Wang, P. J. Walker, and L. L. M. Poon, “Mass extinctions, biodiversity and mitochondrial function: are bats ‘special’ as reservoirs for emerging viruses?,” Curr. Opin. Virol., vol. 1, no. 6, pp. 649–657, Dec. 2011, doi: 10.1016/j.coviro.2011.10.013.

[16] P. Liu et al., “Are pangolins the intermediate host of the 2019 novel coronavirus (SARS-CoV-2)?,” PLOS Pathog., vol. 16, no. 5, p. e1008421, May 2020, doi: 10.1371/journal.ppat.1008421.

[17] I. V. Kuzmin et al., “Bats, emerging infectious diseases, and the rabies paradigm revisited,” Emerg. Health Threats J., vol. 4, no. 1, p. 7159, Jan. 2011, doi: 10.3402/ehtj.v4i0.7159.

[18] X. Zhang, X. Chen, Z. Zhang, A. Roy, and Y. Shen, “Strategies to trace back the origin of COVID-19,” J. Infect., vol. 80, no. 6, pp. e39–e40, Jun. 2020, doi: 10.1016/j.jinf.2020.03.032.

[19] S. Luby et al., “Foodborne Transmission of Nipah Virus, Bangladesh,” Emerg. Infect. Dis., vol. 12, no. 12, pp. 1888–1894, 2006, doi: 10.3201/eid1212.060732.

[20] S.-Q. Deng and H.-J. Peng, “Characteristics of and Public Health Responses to the Coronavirus Disease 2019 Outbreak in China,” J. Clin. Med., vol. 9, no. 2, p. 575, Feb. 2020, doi: 10.3390/jcm9020575.

[21] S. Hamid, M. Y. Mir, and G. K. Rohela, “Novel coronavirus disease (COVID-19): a pandemic (epidemiology, pathogenesis and potential therapeutics),” New Microbes New Infect., vol. 35, p. 100679, May 2020, doi: 10.1016/j.nmni.2020.100679.

[22] L. Cavicchio et al., “Unrevealed genetic diversity of GII Norovirus in the swine population of North East Italy,” Sci. Rep., vol. 10, no. 1, p. 9217, Dec. 2020, doi: 10.1038/s41598-020-66140-4.

[23] A. Wilder-Smith, C. J. Chiew, and V. J. Lee, “Can we contain the COVID-19 outbreak with the same measures as for SARS?,” Lancet Infect. Dis., vol. 20, no. 5, pp. e102–e107, May 2020, doi: 10.1016/S1473-3099(20)30129-8.

[24] S. R. Baker, N. Bloom, S. J. Davis, K. Kost, M. Sammon, and T. Viratyosin, “The Unprecedented Stock Market Reaction to COVID-19,” Rev. Asset Pricing Stud., Jul. 2020, doi: 10.1093/rapstu/raaa008.

[25] M. Lotfi, M. R. Hamblin, and N. Rezaei, “COVID-19: Transmission, prevention, and potential therapeutic opportunities,” Clin. Chim. Acta, vol. 508, pp. 254–266, Sep. 2020, doi: 10.1016/j.cca.2020.05.044.

[26] J. A. Otter, C. Donskey, S. Yezli, S. Douthwaite, S. D. Goldenberg, and D. J. Weber, “Transmission of SARS and MERS coronaviruses and influenza virus in healthcare settings: The possible role of dry surface contamination,” J. Hosp. Infect., vol. 92, no. 3, pp. 235–250, 2016, doi: 10.1016/j.jhin.2015.08.027.

[27] W. J. Wiersinga, A. Rhodes, A. C. Cheng, S. J. Peacock, and H. C. Prescott, “Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19),” JAMA, vol. 324, no. 8, p. 782, Aug. 2020, doi: 10.1001/jama.2020.12839.

[28] C.-C. Lai et al., “Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths,” J. Microbiol. Immunol. Infect., vol. 53, no. 3, pp. 404–412, Jun. 2020, doi: 10.1016/j.jmii.2020.02.012.

[29] N. Chams et al., “COVID-19: A Multidisciplinary Review,” Front. Public Heal., vol. 8, Jul. 2020, doi: 10.3389/fpubh.2020.00383.

[30] N. Chow et al., “Preliminary Estimates of the Prevalence of Selected Underlying Health Conditions Among Patients with Coronavirus Disease 2019 — United States, February 12–March 28, 2020,” MMWR. Morb. Mortal. Wkly. Rep., vol. 69, no. 13, pp. 382–386, Apr. 2020, doi: 10.15585/mmwr.mm6913e2.

[31] J. A. Backer, D. Klinkenberg, and J. Wallinga, “Incubation period of 2019 novel coronavirus (2019-nCoV) infections among travellers from Wuhan, China, 20–28 January 2020,” Eurosurveillance, vol. 25, no. 5, Feb. 2020, doi: 10.2807/1560-7917.ES.2020.25.5.2000062.

[32] N. Donthu and A. Gustafsson, “Effects of COVID-19 on business and research,” J. Bus. Res., vol. 117, pp. 284–289, Sep. 2020, doi: 10.1016/j.jbusres.2020.06.008.

[33] D. Dunning, C. Heath, and J. M. Suls, “Flawed Self-Assessment,” Psychol. Sci. Public Interes., vol. 5, no. 3, pp. 69–106, Dec. 2004, doi: 10.1111/j.1529-1006.2004.00018.x.

[34] P. Howitt et al., “Technologies for global health,” Lancet, vol. 380, no. 9840, pp. 507–535, Aug. 2012, doi: 10.1016/S0140-6736(12)61127-1.

[35] Q. Wang and M. Su, “A preliminary assessment of the impact of COVID-19 on environment – A case study of China,” Sci. Total Environ., vol. 728, p. 138915, Aug. 2020, doi: 10.1016/j.scitotenv.2020.138915.

[36] H. Rajput, R. Changotra, P. Rajput, S. Gautam, A. R. K. Gollakota, and A. S. Arora, “A shock like no other: coronavirus rattles commodity markets,” Environ. Dev. Sustain., Aug. 2020, doi: 10.1007/s10668-020-00934-4.

[37] P. C. Rwigema, “Impact of covid-19 pandemic to meetings, incentives, conferences and exhibitions (MICE) tourism in Rwanda,” Strateg. J. Bus. Chang. Manag., vol. 7, no. 3, pp. 395–409, 2020, [Online]. Available:

[38] O. Atolani et al., “Covid-19: Critical discussion on the applications and implications of chemicals in sanitizers and disinfectants,” EXCLI J., vol. 19, pp. 785–799, 2020, doi: 10.17179/excli2020-2349.

[39] D. Getz and S. J. Page, “Progress and prospects for event tourism research,” Tour. Manag., vol. 52, pp. 593–631, Feb. 2016, doi: 10.1016/j.tourman.2015.03.007.

[40] S. Yezli and A. Khan, “COVID-19 social distancing in the Kingdom of Saudi Arabia: Bold measures in the face of political, economic, social and religious challenges,” Travel Med. Infect. Dis., vol. 37, p. 101692, Sep. 2020, doi: 10.1016/j.tmaid.2020.101692.

[41] J. A. Oldekop et al., “COVID-19 and the case for global development,” World Dev., vol. 134, p. 105044, Oct. 2020, doi: 10.1016/j.worlddev.2020.105044.

[42] S. I. Ivanov, F. J. Jones, and J. K. Zaima, “Analysis of DJIA, S&P 500, S&P 400, NASDAQ 100 and Russell 2000 ETFs and their influence on price discovery,” Glob. Financ. J., vol. 24, no. 3, pp. 171–187, 2013, doi: 10.1016/j.gfj.2013.10.005.

[43] M. Douglas, S. V. Katikireddi, M. Taulbut, M. McKee, and G. McCartney, “Mitigating the wider health effects of covid-19 pandemic response,” BMJ, vol. 369, p. m1557, Apr. 2020, doi: 10.1136/bmj.m1557.

[44] P. K. Ozili and T. Arun, “Spillover of COVID-19: Impact on the Global Economy,” SSRN Electron. J., 2020, doi: 10.2139/ssrn.3562570.

This content is accurate and true to the best of the author’s knowledge and is not meant to substitute for formal and individualized advice from a qualified professional.

© 2020 Michael

Related Articles